Literature DB >> 22198280

PPARα activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4.

Kang Le1, Ruifang Li, Suowen Xu, Xiaoqian Wu, Heqing Huang, Yingxia Bao, Yi Cai, Tian Lan, Joel Moss, Cuixian Li, Jian Zou, Xiaoyan Shen, Peiqing Liu.   

Abstract

Peroxisome proliferator-activated receptor alpha (PPARα) has been implicated in the pathogenesis of cardiac hypertrophy, although its mechanism of action remains largely unknown. To determine the effect of PPARα activation on endothelin-1 (ET-1)-induced cardiomyocyte hypertrophy and explore its molecular mechanisms, we evaluated the interaction of PPARα with nuclear factor of activated T-cells c4 (NFATc4) in nuclei of cardiomyocytes from neonatal rats in primary culture. In ET-1-stimulated cardiomyocytes, data from electrophoretic mobility-shift assays (EMSA) and co-immunoprecipitation (co-IP) revealed that fenofibrate (Fen), a PPARα activator, in a concentration-dependent manner, enhanced the association of NFATc4 with PPARα and decreased its interaction with GATA-4, in promoter complexes involved in activation of the rat brain natriuretic peptide (rBNP) gene. Effects of PPARα overexpression were similar to those of its activation by Fen. PPARα depletion by small interfering RNA abolished inhibitory effects of Fen on NFATc4 binding to GATA-4 and the rBNP DNA. Quantitative RT-PCR and confocal microscopy confirmed inhibitory effects of PPARα activation on elevation of rBNP mRNA levels and ET-1-induced cardiomyocyte hypertrophy. Our results suggest that activated PPARα can compete with GATA-4 binding to NFATc4, thereby decreasing transactivation of NFATc4, and interfering with ET-1 induced cardiomyocyte hypertrophy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198280      PMCID: PMC3506254          DOI: 10.1016/j.abb.2011.11.024

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  48 in total

Review 1.  From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease.

Authors:  R L Nicol; N Frey; E N Olson
Journal:  Annu Rev Genomics Hum Genet       Date:  2000       Impact factor: 8.929

2.  Divergent signaling pathways converge on GATA4 to regulate cardiac hypertrophic gene expression.

Authors:  Qiangrong Liang; Jeffery D Molkentin
Journal:  J Mol Cell Cardiol       Date:  2002-06       Impact factor: 5.000

3.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

Authors:  M N Ghazzi; J E Perez; T K Antonucci; J H Driscoll; S M Huang; B W Faja; R W Whitcomb
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

4.  Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes.

Authors:  Yoko Irukayama-Tomobe; Takashi Miyauchi; Yoshitoshi Kasuya; Satoshi Sakai; Katsutoshi Goto; Iwao Yamaguchi
Journal:  J Cardiovasc Pharmacol       Date:  2004-11       Impact factor: 3.105

Review 5.  Peroxisome proliferator-activated receptor alpha and hypertensive heart disease.

Authors:  Maria J Goikoetxea; Javier Beaumont; Javier Díez
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy.

Authors:  H E Shubeita; P M McDonough; A N Harris; K U Knowlton; C C Glembotski; J H Brown; K R Chien
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

7.  Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation.

Authors:  Anna Planavila; Juan C Laguna; Manuel Vázquez-Carrera
Journal:  Biochim Biophys Acta       Date:  2005-02-21

8.  Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy.

Authors:  M A Bogoyevitch; P E Glennon; M B Andersson; A Clerk; A Lazou; C J Marshall; P J Parker; P H Sugden
Journal:  J Biol Chem       Date:  1994-01-14       Impact factor: 5.157

9.  Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy.

Authors:  Ruifang Li; Wenhua Zheng; Rongbiao Pi; Jie Gao; Huijie Zhang; Ping Wang; Kang Le; Peiqing Liu
Journal:  FEBS Lett       Date:  2007-06-19       Impact factor: 4.124

10.  The epidemiology of heart failure: the Framingham Study.

Authors:  K K Ho; J L Pinsky; W B Kannel; D Levy
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

View more
  11 in total

1.  Fenofibrate unexpectedly induces cardiac hypertrophy in mice lacking MuRF1.

Authors:  Traci L Parry; Gopal Desai; Jonathan C Schisler; Luge Li; Megan T Quintana; Natalie Stanley; Pamela Lockyer; Cam Patterson; Monte S Willis
Journal:  Cardiovasc Pathol       Date:  2015-10-29       Impact factor: 2.185

2.  Peroxisome Proliferator-Activated Receptor α Reduces Endothelin-1-Caused Cardiomyocyte Hypertrophy by Inhibiting Nuclear Factor-κB and Adiponectin.

Authors:  Hsu-Lung Jen; Po-Len Liu; Yung-Hsiang Chen; Wei-Hsian Yin; Jaw-Wen Chen; Shing-Jong Lin
Journal:  Mediators Inflamm       Date:  2016-10-11       Impact factor: 4.711

3.  Hydroxysafflor Yellow A Attenuates the Apoptosis of Peripheral Blood CD4+ T Lymphocytes in a Murine Model of Sepsis.

Authors:  Jinping Wang; Ping Wang; Shuiqing Gui; Yun Li; Runhua Chen; Renqing Zeng; Peiyan Zhao; Hanwei Wu; Zheyu Huang; Jianlong Wu
Journal:  Front Pharmacol       Date:  2017-09-06       Impact factor: 5.810

4.  Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis.

Authors:  Si-Chi Xu; Zhen-Guo Ma; Wen-Ying Wei; Yu-Pei Yuan; Qi-Zhu Tang
Journal:  PPAR Res       Date:  2017-01-03       Impact factor: 4.964

Review 5.  Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.

Authors:  Xiaojun Feng; Antoni Sureda; Samineh Jafari; Zahra Memariani; Devesh Tewari; Giuseppe Annunziata; Luigi Barrea; Sherif T S Hassan; Karel Šmejkal; Milan Malaník; Alice Sychrová; Davide Barreca; Lovro Ziberna; Mohamad Fawzi Mahomoodally; Gokhan Zengin; Suowen Xu; Seyed Mohammad Nabavi; Ai-Zong Shen
Journal:  Theranostics       Date:  2019-03-16       Impact factor: 11.556

6.  SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity.

Authors:  Xiaojun Feng; Yanan Wang; Wenxu Chen; Suowen Xu; Lingli Li; Yadi Geng; Aizong Shen; Hui Gao; Lei Zhang; Sheng Liu
Journal:  Aging (Albany NY)       Date:  2020-03-04       Impact factor: 5.682

7.  Suberanilohydroxamic Acid as a Pharmacological Kruppel-Like Factor 2 Activator That Represses Vascular Inflammation and Atherosclerosis.

Authors:  Yanni Xu; Suowen Xu; Peng Liu; Marina Koroleva; Shuya Zhang; Shuyi Si; Zheng Gen Jin
Journal:  J Am Heart Assoc       Date:  2017-11-30       Impact factor: 5.501

8.  Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin.

Authors:  Hsu-Lung Jen; Wei-Hsian Yin; Jaw-Wen Chen; Shing-Jong Lin
Journal:  J Atheroscler Thromb       Date:  2016-09-15       Impact factor: 4.928

9.  Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.

Authors:  Suowen Xu; Yanni Xu; Meimei Yin; Shuya Zhang; Peng Liu; Marina Koroleva; Shuyi Si; Peter J Little; Jaroslav Pelisek; Zheng Gen Jin
Journal:  Theranostics       Date:  2018-04-30       Impact factor: 11.556

10.  NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity.

Authors:  Xin Zhang; Fang Lei; Xiao-Ming Wang; Ke-Qiong Deng; Yan-Xiao Ji; Yan Zhang; Hongliang Li; Xiao-Dong Zhang; Zhibing Lu; Peng Zhang
Journal:  J Am Heart Assoc       Date:  2020-08-04       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.